| Michael Lloyd Petranek, DPM | |
|
9918 Main St, Fairfax, VA 22031-3901 | |
| (703) 273-9818 | |
| (866) 453-6775 |
| Full Name | Michael Lloyd Petranek |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 21 Years |
| Location | 9918 Main St, Fairfax, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265449508 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 507 (North Carolina) | Secondary |
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 0103300947 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Foot And Ankle Specialists Of The Mid-atlantic Llc | 6305017633 | 147 |
| Foot And Ankle Specialists Of The Mid-atlantic Llc | 6305017633 | 147 |
News Archive
A study published today in Nature Genetics has revealed mutations that could have a major impact on the future diagnosis and treatment of many human diseases.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
In an effort to limit possible prescription narcotic misuse and dependence among its members, Blue Cross Blue Shield of Massachusetts (BCBSMA) announced today that it is instituting enhanced safety measures on how it will cover the use of powerful pain killers.
A new study by researchers in China and the U.S. describes a round-up of the effects of commonly used hypoglycemic drugs on the outcomes of COVID-19 in diabetic patients.
Researchers at Umeå University in Sweden have discovered a genetic mutation that can cause dissection of the thoracic aorta, which is the body's main artery.
› Verified 6 days ago
| Provider Name | Richard Mendelsohn |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1174516819 PECOS PAC ID: 9032145594 Enrollment ID: I20050715000357 |
News Archive
A study published today in Nature Genetics has revealed mutations that could have a major impact on the future diagnosis and treatment of many human diseases.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
In an effort to limit possible prescription narcotic misuse and dependence among its members, Blue Cross Blue Shield of Massachusetts (BCBSMA) announced today that it is instituting enhanced safety measures on how it will cover the use of powerful pain killers.
A new study by researchers in China and the U.S. describes a round-up of the effects of commonly used hypoglycemic drugs on the outcomes of COVID-19 in diabetic patients.
Researchers at Umeå University in Sweden have discovered a genetic mutation that can cause dissection of the thoracic aorta, which is the body's main artery.
› Verified 6 days ago
| Provider Name | Foot And Ankle Specialists Of The Mid-atlantic Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1073804712 PECOS PAC ID: 6305017633 Enrollment ID: O20170424001337 |
News Archive
A study published today in Nature Genetics has revealed mutations that could have a major impact on the future diagnosis and treatment of many human diseases.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
In an effort to limit possible prescription narcotic misuse and dependence among its members, Blue Cross Blue Shield of Massachusetts (BCBSMA) announced today that it is instituting enhanced safety measures on how it will cover the use of powerful pain killers.
A new study by researchers in China and the U.S. describes a round-up of the effects of commonly used hypoglycemic drugs on the outcomes of COVID-19 in diabetic patients.
Researchers at Umeå University in Sweden have discovered a genetic mutation that can cause dissection of the thoracic aorta, which is the body's main artery.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Lloyd Petranek, DPM 9918 Main St, Fairfax, VA 22031-3901 Ph: (703) 273-9818 | Michael Lloyd Petranek, DPM 9918 Main St, Fairfax, VA 22031-3901 Ph: (703) 273-9818 |
News Archive
A study published today in Nature Genetics has revealed mutations that could have a major impact on the future diagnosis and treatment of many human diseases.
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.
In an effort to limit possible prescription narcotic misuse and dependence among its members, Blue Cross Blue Shield of Massachusetts (BCBSMA) announced today that it is instituting enhanced safety measures on how it will cover the use of powerful pain killers.
A new study by researchers in China and the U.S. describes a round-up of the effects of commonly used hypoglycemic drugs on the outcomes of COVID-19 in diabetic patients.
Researchers at Umeå University in Sweden have discovered a genetic mutation that can cause dissection of the thoracic aorta, which is the body's main artery.
› Verified 6 days ago
Dr. Rostana Said, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 10721 Main St, Suite 103, Fairfax, VA 22030 Phone: 703-273-3622 | |
Fair Oaks Podiatry And Sports Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3620 Joseph Siewick Dr, 303, Fairfax, VA 22033 Phone: 703-865-6783 Fax: 703-865-6784 | |
Fairfax Foot And Ankle Specialists, Pllc Podiatrist Medicare: Medicare Enrolled Practice Location: 10875 Main St Ste 212, Fairfax, VA 22030 Phone: 203-494-6958 | |
Dr. Richard Scott Mendelsohn, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 9918 Main St, Fairfax, VA 22031 Phone: 703-273-9818 Fax: 703-832-8307 | |
Dr. Jugal Dharia, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 10721 Main St Ste 3500, Fairfax, VA 22030 Phone: 703-352-8888 Fax: 703-352-8994 | |
Dr. Hsin-yi Steve Hsu, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 8301 Arlington Blvd, Suite 508, Fairfax, VA 22031 Phone: 703-560-4321 | |
Robert M Hallivis, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 3998 Fair Ridge Dr Ste 280, Fairfax, VA 22033 Phone: 703-849-8400 Fax: 703-849-8448 |